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FoxO transcription factors contribute to cardiac muscle remodeling and insulin signaling, but how they link
insulin resistance and maladaptive heart hypertrophy remains unknown. A new study by Ni et al. (2007) shows
that sustained activation of FoxO1 or FoxO3 in cardiomyocytes selectively enhances the activity of Akt/PKB
and reduces insulin signaling through inhibition of calcineurin and PP2A.With the recognition that individuals with
the metabolic syndrome have a doubling
of their risk for cardiovascular disease
and an approximately five-fold increase
in their likelihood of developing type II di-
abetes, an understanding of the underly-
ing molecular mechanisms linking the
syndrome with these two diseases has
been a central aim of metabolic research
(Grundy, 2008). Systemic risk factors of
the metabolic syndrome such as hy-
perglycemia, atherogenic dyslipidemia,
increased blood pressure, and prothrom-
botic and proinflammatory states are well
recognized to seriously impact heart func-
tion. Indeed, pharmacological reduction
of postprandial hyperglycemia leads to
a decrease in ventricular dimension and
improvement of chronic heart failure
associated with type II diabetes (Node,
2006). Although less recognized, insulin
resistance is directly linked to cardiac
hypertrophic growth and thus enhances
the cardiac risk factors associated with
the metabolic syndrome. Therefore, there
is considerable interest in understanding
the mechanisms that underlie insulin
resistance and pathogenic myocardial
growth. A recent study by Ni et al. (2007)
provides such a link by demonstrating
that FoxO1 and FoxO3, two members of
the O subfamily of the forkhead/winged-
helix transcription factors that play im-
portant roles in the regulation of heart
remodeling, attenuate insulin signaling in
cardiomyocytes via inhibition of protein
phosphatases.
In the heart, several pathways have
been identified to play a role in cardiac hy-
pertrophy, components of which include
transcription factors, G protein-coupled
receptors, kinases, and even microRNAs(Care et al., 2007; Frey et al., 2004).
For example, the phosphatidylinositol
3-kinase (PI3K) pathway is of crucial
importance in modulating cardiomyocyte
growth and survival (Figure 1). Through
its action on several key substrates, in-
cluding mTOR complex 1 (mTORC1),
Akt/PKB activation leads to an increase
in protein translation and ribosome bio-
genesis necessary for heart hypertrophy.
In parallel, the Akt/PKB kinase also
promotes cardiomyocyte hypertrophy
through a different cascade that is partic-
ularly important in the heart. Through
phosphorylation of FoxO transcription
factors, Akt/PKB promotes the cytoplas-
mic sequestration of these transcription
factors and prevents FoxO-mediated
transcription of several proapoptotic
genes and the expression of the atrogin-
1/MAFbx proteasomal factor (Huang and
Tindall, 2007). Atrogin-1 proteasomal ac-
tivity is known to target the degradation
of calcineurin, an important phosphatase
that activates a second cascade of gene
regulation through the nuclear factor of
activated T cell 1 (NFAT1) transcription
factor. NFAT1 directly controls the ex-
pression of several genes involved in
cardiomyocyte growth (Figure 1). Thus,
in part through this relatively simple linear
cascade, it has been possible to molecu-
larly link insulin stimulation present in the
metabolic syndrome to its propensity to
promote cardiac hypertrophy.
However, a recent report by the Hill
laboratory points to much more complex
feedback regulation that positions FoxO
proteins as central players in the control
of this entire cascade (Ni et al., 2007). Us-
ing adenoviral vectors expressing FoxO1
and FoxO3 as well as a constitutivelyCell Metabolismactivated FoxO1 mutant, they observed
that endogenous Akt/PKB becomes hy-
perphosphorylated in primary cardiomyo-
cytes. This phosphorylation is associated
with an increase in kinase activity, but not
a rise in protein levels. Interestingly, this
gain in activity appeared to be preferen-
tially directed toward FoxO itself, and
not toward other known Akt/PKB targets.
This finding alone supports the unique-
ness of this feedback loop in the heart. Al-
though the experiments were performed
with primary cardiomyocytes, it would
be of interest to confirm the physiological
relevance of these observations by forced
expression of FoxO proteins in mouse
hearts.
As transcription factors, FoxO1 and
FoxO3 are likely to modify Akt/PKB phos-
phorylation indirectly by modifying the
expression of kinases or phosphatases
that target Akt/PKB. Therefore, the au-
thors then show that, as they had reported
previously (Ni et al., 2006), an increase in
wild-type or constitutively active FoxO
expression causes a corresponding re-
duction in PP2A activity but, more strik-
ingly, a significant drop in calcineurin
(PP2B) activity. Although PP2A had been
shown to target Akt/PKB, calcineurin
had not previously been identified as an
Akt/PKB phosphatase. Interestingly, Ni
et al. (2007) verified this by demonstrating
that in the presence of increased levels of
calcineurin, Akt/PKB phosphorylation and
activity were decreased. In contrast,
an increase in the calcineurin inhibitor
MCIP1.4 or treatment with FK506, a clini-
cally relevant inhibitor of calcineurin,
caused a direct increase in both phos-
phorylation and activity of Akt/PKB. A
negative regulation of calcineurin by7, February 2008 ª2008 Elsevier Inc. 101
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ability to increase the transcription of the
muscle-specific ubiquitin ligase atrogin-
1, which targets calcineurin as well as
other key components ofmyocyte growth.
In fact, it has been reported that the same
FoxO-atrogin-1 link inhibits skeletal mus-
cle atrophy when blocked by expression
of the transcriptional coactivator PGC-1a
(Sandri et al., 2006). This feedback loop
with FoxO is clearly not aminor phenome-
non with respect to Akt/PKB because in-
sulin stimulation of cardiomyocytes as de-
tected by Akt/PKB phosphorylation and
by glucose uptake is severely blunted in
the presence of high levels of FoxO. Taken
together, the data of Ni et al. (2007) pres-
ent a clearer picture of an important feed-
back loop in cardiomyocytes, one that
likely ensures that, in normal glycemic
conditions, insulin-dependent stimulation
of the PI3K pathway does not lead to
cardiac hypertrophy.
A similar feedback loop had previously
been reported in the liver (Matsumoto102 Cell Metabolism 7, February 2008 ª2008et al., 2006); however, important differ-
ences exist. For example, the general
effect of FoxO on Akt/PKB activity also in-
cluded changes in GSK3 phosphorylation
in hepatocytes. This was not detected in
cardiomyocytes by Ni et al. (2007). The
modulation of FoxO1 or FoxO3’s activa-
tion of Akt/PKB is proposed by Ni et al.
to be a potential avenue for the treatment
of the metabolic syndrome, insulin resis-
tance, and associated pathologic cardiac
hypertrophy. This is a challenging pro-
posal, as the activities of the four known
FoxO proteins are tightly controlled by di-
verse posttranslational mechanisms. Ex-
pressed in almost every tissue, the FoxO
proteins have been associated with an ex-
tensive array of transcriptional targets and
physiological functions (Matsumoto et al.,
2006). From cell-cycle modulation and
protection against oxidative stress dam-
ages to metabolic and growth control
functions, they have major implications
in mammalian physiology. However, if
we focus on the heart, FoxO activity isElsevier Inc.decreased during cardiac hypertrophy,
likely because of an increase in the activity
of the Akt/PKB pathway. Therefore, spe-
cifically augmenting the level of active
FoxO3 in the heart would potentially result
in reduced cardiac hypertrophy and per-
haps decrease other aspects of the meta-
bolic syndrome. Although some variations
in FoxO mRNA expression are known to
exist in different tissues and under various
stimuli, it is the different protein process-
ing mechanisms such as phosphoryla-
tion, acetylation, proteolytic cleavage,
and proteasomal degradation that are
the main regulators of FoxO functionality.
For example, although Akt/PKB phos-
phorylation of FoxO excludes it from the
nucleus, under oxidative stress, Jun N-
terminal kinase (JNK) phosphorylates
FoxO proteins on a different site than
PKB/Akt, which results in FoxO accumu-
lation in the nucleus. It may thus be possi-
ble to act through these additional FoxO-
modulating pathways to influence the
availability and activity of FoxO proteins.
Alternatively, as shown recently by Li
et al. (2007), atrogin-1 regulation of cardi-
omyocyte growth may also be a potential
therapeutic direction to pursue. Because
of its intrinsic role in activating protein
degradation as a coactivator of the FoxO
proteins, perhaps modulation of the activ-
ity of the atrogin-1 proteasome complex
would improve the metabolic syndrome
associated with cardiac hypertrophy.
Another potential therapeutic direction
might be to employ known inhibitors of
calcineurin, such as cyclosporin A (CsA)
or FK506. Although they are quite effective
in decreasing calcineurin activity, these
drugs nevertheless exhibit undesired
side effects and toxicity. As shown by Yu
et al. (2007), a potentially more promising
approach may be to directly target NFAT
using inhibitors such as the synthetic
peptide VIVIT. It remains to be seen
whether this approach will elicit side
effects and toxicity similar to those seen
with calcineurin inhibitors, particularly
when a long-term treatment strategy for
metabolic syndrome-induced cardiac hy-
pertrophy is likely to be required. Overall,
the work by Hill’s laboratory brings a new
perspective to the once linear PI3K path-
way and to the role of FoxOproteinswithin
amorecomplex, but potentiallymore ther-
apeutically amenable, network of mole-
cules involved in insulin signaling and cell
growth in cardiomyocytes.Figure 1. Feedback Mechanism of FoxO Transcription Factors and Cardiac Hypertrophy
Abnormal activation of cardiomyocyte insulin receptors in patients with the metabolic syndrome triggers
the PI3K-Akt/PKB signaling pathway, resulting in increased protein translation and ribosome biogenesis.
In parallel, Akt/PKB phosphorylation of FoxO promotes its segregation in the cytoplasm. The absence of
active nuclear FoxO prevents the transcription of atrogin-1, which normally targets calcineurin for degra-
dation. Calcineurin is then able to activate NFAT, leading to heart hypertrophy. However, overexpression
of FoxO can bypass its negative regulation by Akt/PKB and augments the production of atrogin-1, causing
the subsequent degradation of calcineurin and protection against cardiac hypertrophy. If sufficient calci-
neurin or PP2A is present, FoxO promotes the dephosphorylation of Akt/PKB, inhibiting the downstream
signaling cascade. Prevention of heart hypertrophy could therefore potentially be achieved by treatment
with either calcineurin inhibitors (CsA or FK506) or NFAT inhibitors such as VIVIT.
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